Join our daily newsletter At The Bell to receive exclusive market insights
AFT Pharmaceuticals has “lots of exciting things happening” as FY26 begins, not least Combogesic IV launching in Canada as the New Zealand pharma company looks to build its presence in North America in coming months and years.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
“We’re making very good progress, we’re working with Hikma [Pharmaceutical], which is actually now the second largest supplier of injectable products into the U.S. ā and we’ve extended our agreement to include tablets as well,” AFT Pharma’s managing director, Hartley Atkinson, told HotCopper.
Combogesic IV combines 1000 milligrams paracetamol and 300mg ibuprofen in a single injectable formulation for the treatment of mild to moderate pain.
Alongside this month’s “exciting” Canadian expansion, AFT Pharma is also working on research and development programs that include:
- Pre-Investigational New Drug application (pre-IND) for its antibiotic eyedrop, which is already filed (IND to be filed with the FDA this year);
- Preparing to file a further pre-IND application for our Strawberry Birth Marks topical treatment this year;
- Preparing to file an IND for the novel iron injection around year-end;
- Additional further projects for improved formulation.
“We’re really excited about all our R&D projects,” Mr Atkinson said on the suite.
Join the discussion: See what HotCopper users are saying about AFT Pharmaceuticals and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
